• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 40-17F2 filed by Daxor Corporation

    6/11/25 6:03:28 AM ET
    $DXR
    Medical/Dental Instruments
    Health Care
    Get the next $DXR alert in real time by email
    40-17F2 1 form40-17f2.htm 40-17F2

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM N-17f-2

     

    Certificate of Accounting of Securities and Similar

    Investments in the Custody of

    Management Investment Companies

     

    Pursuant to Rule 17f-2 [17 CFR 270.17f-2]

     

    1. Investment Company Act File Number: 811-22684   Date examination completed:
             
        July 31, 2024
    2. State identification Number:
        AL   AK   AZ   AR   CA   CO
        CT   DE   DC   FL   GA   HI
        ID   IL   IN   IA   KS   KY
        LA   ME   MD   MA   MI   MN
        MS   MO   MT   NE   NV   NH
        NJ   NM   NY X   NC   ND   OH
        OK   OR   PA   RI   SC   SD
        TN   TX   UT   VT   VA   WA
        WV   WI   WY   PUERTO RICO        
       

    Other

    (specify):

     

                       
    3. Exact name of investment company as specified in registration statement:
     
    Daxor Corporation
     
    4. Address of principal executive office (number, street, city, state, zip code):
     

    109 Meco Lane, Oak Ridge, TN 37830

     

     

     

     

     
     

     

     

    Management Statement Regarding Compliance with

    Certain Provisions of the Investment Company Act of 1940

     

    March 3, 2025

     

    We, as members of management of Daxor Corporation, (the “Company”) are responsible for complying with the requirements of subsections (b) and (c) of Rule 17f-2, “Custody of Investments by Registered Management Investment Companies,” of the Investment Company Act of 1940. We are also responsible for establishing and maintaining effective internal controls over compliance with those requirements. We have performed an evaluation of the Company’s compliance with the requirements of subsections (b) and (c) of Rule 17f-2 as of July 31, 2024, and for the period from December 31, 2023 through July 31, 2024.

     

    Based on this evaluation, we assert that the Company was in compliance with the requirements of subsections (b) and (c) of Rule 17f-2 of the Investment Company Act of 1940 as of December 31, 2024, and for the period from December 31, 2023 through July 31, 2024, with respect to securities reflected in the investment accounts of the Company.

     

    Daxor Corporation  
       
    /s/ Michael Feldschuh  
    Michael Feldschuh  
    President and Chief Executive Officer  
       
    /s/ Robert J. Michel  
    Robert J. Michel  
    Chief Financial Officer  
    Chief Compliance Officer  

     

     
     

     

    Independent Public Accountant’s Report

     

    To the Board of Directors and Shareholders of Daxor Corporation,

     

    We have examined management of Daxor Corporation (the “Company”) assertion, included in the accompanying Management Statement Regarding Compliance with Certain Provisions of the Investment Company Act of 1940, that the Company complied with the requirements of subsections (b) and (c) of Rule 17f-2, under the Investment Company Act of 1940 (the “Act’’) (the “specified requirements”) as of July 31, 2024. Daxor Corporation’s management is responsible for its assertion. Our responsibility is to express an opinion on management’s assertion about the Company’s compliance with the specified requirements based on our examination.

     

    Our examination was conducted in accordance with attestation standards established by the AICPA. Those standards require that we plan and perform the examination to obtain reasonable assurance about whether management’s assertion about compliance with the specified requirements is fairly stated, in all material respects. An examination involves performing procedures to obtain evidence about whether management’s assertion is fairly stated in all material respects. The nature, timing, and extent of the procedures selected depend on our judgement, including an assessment of the risks of material misstatement of management’s assertion, whether due to fraud or error. We believe that the evidence we obtained is sufficient and appropriate to provide a reasonable basis for our opinion.

     

    We are required to be independent and to meet our other ethical responsibilities in accordance with relevant ethical requirements relating to the engagement.

     

    Included among our procedures were the following tests performed as of July 31, 2024, and with respect to the agreement of security purchases and sales, for the period from December 31, 2023 (the date of the last examination), through July 31, 2024:

     

    ●Confirmation of all securities held by custodians in book entry form including UBS Financial Services Inc. and Continental Stock Transfer & Trust
    ●Reconciliation of all such securities to the books and records of the Company and the custodians
    ●Agreement of all security purchases and all security sales or maturities since the last report from the books and records of the Company to custodian confirmations

     

    Our examination does not provide a legal determination on the Company’s compliance with the specified requirements.

     

    In our opinion, management’s assertion that Daxor Corporation complied with the requirements of subsections (b) and (c) of Rule 17f-2 of the Investment Company Act of 1940 as of July 31, 2024, with respect to securities reflected in the investment account of the Company is fairly stated, in all material respects.

     

    This report is intended solely for the information and use of management and the Board of Directors of Daxor Corporation and the Securities and Exchange Commission and is not intended to be, and should not be, used by anyone other than the specified parties.

     

    /s/ Bush & Associates CPA LLC

     

    We have served as the Company’s auditor since 2024.

     

    Henderson, Nevada

    March 3, 2025

    PCAOB ID Number 6797

     

     

     

     

    Get the next $DXR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DXR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DXR
    SEC Filings

    See more
    • SEC Form 40-17F2 filed by Daxor Corporation

      40-17F2 - DAXOR CORP (0000027367) (Subject)

      6/13/25 6:22:14 AM ET
      $DXR
      Medical/Dental Instruments
      Health Care
    • SEC Form 40-17F2 filed by Daxor Corporation

      40-17F2 - DAXOR CORP (0000027367) (Subject)

      6/12/25 6:37:07 AM ET
      $DXR
      Medical/Dental Instruments
      Health Care
    • SEC Form 40-17F2 filed by Daxor Corporation

      40-17F2 - DAXOR CORP (0000027367) (Subject)

      6/11/25 6:03:28 AM ET
      $DXR
      Medical/Dental Instruments
      Health Care

    $DXR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal

      Published Research Demonstrates the Value of BVA in Meeting Key Goal of Identifying Anemia in Heart Failure Patients Oak Ridge, TN, May 14, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), Daxor Corporation, the global leader in blood volume measurement technology, today announces significant new findings from Duke University Medical Center published in the prestigious American Heart Journal. The research demonstrates how Blood Volume Analysis (BVA) enables precise measurement of red blood cell mass (RBCM) and effectively differentiates between true and dilutional anemia in heart failure (HF) patients. The detection of true anemia and its management is a key part of Heart Failur

      5/14/25 8:00:00 AM ET
      $DXR
      Medical/Dental Instruments
      Health Care
    • Daxor's Blood Volume Analysis Diagnostic Reaches Two New U.S. Healthcare Systems

      Gold-Standard Technology Now Available in East Tennessee and Pacific Northwest Through Strategic Dual-Model Implementation Oak Ridge, TN, May 13, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), Daxor Corporation, the global leader in blood volume measurement technology, announces the expansion of its innovative diagnostic solutions into two additional U.S. healthcare systems, further advancing the standard of care for cardiovascular and critical care patients nationwide. Daxor continues to drive healthcare transformation through its dual implementation models, tailored to meet the unique needs of diverse clinical settings. This strategic expansion includes: A premier regional r

      5/13/25 8:00:00 AM ET
      $DXR
      Medical/Dental Instruments
      Health Care
    • Florida Healthcare Leader Embraces Daxor Blood Volume Analysis Technology

      Daxor's ezBVA Lab Service Marks New Standard in Precision Fluid Management Oak Ridge, TN, May 07, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces the opening of a new BVA program at a premier Florida healthcare center in the Tampa Bay region. This expansion integrates Daxor's innovative blood volume analysis (BVA) testing across the facility's inpatient and outpatient care programs, revolutionizing fluid management precision and enhancing treatment outcomes for a spectrum of conditions. The facility will utilize Daxor's state-of-the-art Tennessee-based CLIA-certified ezBVA Lab that delivers comprehensive b

      5/7/25 8:00:00 AM ET
      $DXR
      Medical/Dental Instruments
      Health Care